Chenming Zhao1,2, Yuri Tolkach3, Doris Schmidt1, Marieta Toma3, Michael H Muders3, Glen Kristiansen3, Stefan C Müller1, Jörg Ellinger4,5. 1. Department of Urology, University Hospital Bonn, Bonn, Germany. 2. Department of Urology, Second Hospital of Hebei Medical University, Shijiazhuang, China. 3. Department of Pathology, University Hospital Bonn, Bonn, Germany. 4. Department of Urology, University Hospital Bonn, Bonn, Germany. joerg.ellinger@ukbonn.de. 5. Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Bonn, Sigmund-Freud-Strasse 25, 53127, Bonn, Germany. joerg.ellinger@ukbonn.de.
Abstract
PURPOSE: PIWI-interacting RNAs (piRNAs) have been suggested to serve as biomarkers in cancer. In this study, we validated the expression profile of two piRNAs derived from mitochondria, piR-34536 and piR-51810, in tissue and serum of a cohort of clear cell renal cell carcinoma (ccRCC) patients. METHODS: Tissue and serum samples of patients with ccRCC were collected prospectively in our biobank. Total RNA was isolated from 118 ccRCC tissues, 75 normal renal tissues as well as 30 serum samples from patients with ccRCC, and 15 serum samples from patients with non-malignant diseases. The expression of piRNAs was determined using quantitative real-time PCR. RESULTS: Both piR-34536 and piR-51810 were downregulated in ccRCC compared to non-malignant renal tissue. Decreased tissue piRNA levels were significant and independent predictors of shortened progression-free, cancer-specific and overall survival of ccRCC patients. The piRNA levels in serum did not differ in ccRCC patients and control subjects. CONCLUSIONS: The expression of piR-34536 and piR-51810 in ccRCC tissues may be used as prognostic biomarkers in ccRCC.
PURPOSE: PIWI-interacting RNAs (piRNAs) have been suggested to serve as biomarkers in cancer. In this study, we validated the expression profile of two piRNAs derived from mitochondria, piR-34536 and piR-51810, in tissue and serum of a cohort of clear cell renal cell carcinoma (ccRCC) patients. METHODS: Tissue and serum samples of patients with ccRCC were collected prospectively in our biobank. Total RNA was isolated from 118 ccRCC tissues, 75 normal renal tissues as well as 30 serum samples from patients with ccRCC, and 15 serum samples from patients with non-malignant diseases. The expression of piRNAs was determined using quantitative real-time PCR. RESULTS: Both piR-34536 and piR-51810 were downregulated in ccRCC compared to non-malignant renal tissue. Decreased tissue piRNA levels were significant and independent predictors of shortened progression-free, cancer-specific and overall survival of ccRCC patients. The piRNA levels in serum did not differ in ccRCC patients and control subjects. CONCLUSIONS: The expression of piR-34536 and piR-51810 in ccRCC tissues may be used as prognostic biomarkers in ccRCC.
Authors: David C Johnson; Josip Vukina; Angela B Smith; Anne-Marie Meyer; Stephanie B Wheeler; Tzy-Mey Kuo; Hung-Jui Tan; Michael E Woods; Mathew C Raynor; Eric M Wallen; Raj S Pruthi; Matthew E Nielsen Journal: J Urol Date: 2014-07-27 Impact factor: 7.450
Authors: Kevin W Ng; Christine Anderson; Erin A Marshall; Brenda C Minatel; Katey S S Enfield; Heather L Saprunoff; Wan L Lam; Victor D Martinez Journal: Mol Cancer Date: 2016-01-15 Impact factor: 27.401